AR-13503
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


AR-13503
Description:
AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research[1][2][3].Product Name Alternative:
AR-13324 M1 metaboliteUNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
PKC; ROCKType:
Reference compoundRelated Pathways:
Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Stem Cell/Wnt; TGF-beta/SmadField of Research:
Neurological Disease; Cardiovascular DiseaseAssay Protocol:
https://www.medchemexpress.com/ar-13503.htmlPurity:
98.21Solubility:
DMSO : 40 mg/mL (ultrasonic; adjust pH to 3 with HCl)Smiles:
OCC1=CC=C([C@@H](CN)C(NC2=CC(C=CN=C3)=C3C=C2)=O)C=C1Molecular Formula:
C19H19N3O2Molecular Weight:
321.38Precautions:
H302, H315, H319, H335References & Citations:
[1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205.|[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.|[3]Halasz E, et al. AR-13503, a ROCK inhibitor, reduces rod axon retraction during retinal detachment[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 4221-4221.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
Phase 1CAS Number:
[2309668-15-1]
